Research ArticleTheranostics
α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colon Cancer Xenografts
Sandra Heskamp, Reinier Hernandez, Janneke D.M. Molkenboer-Kuenen, Markus Essler, Frank Bruchertseifer, Alfred Morgenstern, Erik J. Steenbergen, Weibo Cai, Christof Seidl, William J. McBride, David M. Goldenberg and Otto C. Boerman
Journal of Nuclear Medicine June 2017, 58 (6) 926-933; DOI: https://doi.org/10.2967/jnumed.116.187021
Sandra Heskamp
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Reinier Hernandez
2Medical Physics Department, University of Wisconsin–Madison, Madison, Wisconsin
Janneke D.M. Molkenboer-Kuenen
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Markus Essler
3Klinik und Poliklinik fur Nuklearmedizin, University of Bonn, Bonn, Germany
Frank Bruchertseifer
4European Commission, Joint Research Centre–Directorate for Nuclear Safety and Security, Karlsruhe, Germany
Alfred Morgenstern
4European Commission, Joint Research Centre–Directorate for Nuclear Safety and Security, Karlsruhe, Germany
Erik J. Steenbergen
5Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
Weibo Cai
2Medical Physics Department, University of Wisconsin–Madison, Madison, Wisconsin
Christof Seidl
6Department of Nuclear Medicine, Technische Universität München, Munich, Germany
7Department of Obstetrics and Gynecology, Technische Universität München, Munich, Germany; and
William J. McBride
8Immunomedics, Inc., Morris Plains, New Jersey
David M. Goldenberg
8Immunomedics, Inc., Morris Plains, New Jersey
Otto C. Boerman
1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 6
June 1, 2017
α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colon Cancer Xenografts
Sandra Heskamp, Reinier Hernandez, Janneke D.M. Molkenboer-Kuenen, Markus Essler, Frank Bruchertseifer, Alfred Morgenstern, Erik J. Steenbergen, Weibo Cai, Christof Seidl, William J. McBride, David M. Goldenberg, Otto C. Boerman
Journal of Nuclear Medicine Jun 2017, 58 (6) 926-933; DOI: 10.2967/jnumed.116.187021
α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colon Cancer Xenografts
Sandra Heskamp, Reinier Hernandez, Janneke D.M. Molkenboer-Kuenen, Markus Essler, Frank Bruchertseifer, Alfred Morgenstern, Erik J. Steenbergen, Weibo Cai, Christof Seidl, William J. McBride, David M. Goldenberg, Otto C. Boerman
Journal of Nuclear Medicine Jun 2017, 58 (6) 926-933; DOI: 10.2967/jnumed.116.187021
Jump to section
Related Articles
Cited By...
- Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten
- Efficacy of HER2-Targeted Intraperitoneal 225Ac {alpha}-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis
- Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor response in prostate cancer
- Pretargeting: A Path Forward for Radioimmunotherapy
- Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy